International: +1-347-960-6455
Intermittent Claudication Therapeutics - Pipeline Analysis 2018

Intermittent Claudication Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10085 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Musculoskeletal
Select License Type

Intermittent claudication refers to aching or squeezing pain in thighs, buttocks or feet during exercise, due to insufficient blood circulation resulting from peripheral arterial disease. The probability of developing peripheral arterial disease increases with the age. Smoking, high blood pressure, atherosclerosis, diabetes, and high cholesterol are some of the risk factors associated with the development of peripheral arterial disease, resulting in intermittent claudication. Intermittent claudication is detected by the pulse and blood pressure in legs and by arteriogram. The standard treatments available for intermittent claudication are angioplasty and surgery. Pluristem Ltd. is in the process of developing PLX-PAD for the treatment of intermittent claudication associated with peripheral arterial disease. Some of the companies involved in intermittent claudication pipeline include Kowa Company Ltd., and Nissan Chemical Industries Ltd. Among others.

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.